Back to Atlas
APotentially durableResearch-only / high verification need
CMP-0042
Approved cardiac drug; senolytic use not approved
Digoxin
Senolytic / Cardiac glycoside
Senescent-cell killing reported in preclinical screens
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Cardiac glycoside
- Primary mechanism
- Na+/K+-ATPase inhibition; apoptotic vulnerability in senescent cells
- Primary market use
- Cardiology / senolytic research
Pharmacology
- Molecular weight (Da)
- 780.94
- Oral bioavailability
- Oral; ~60-80%
- Half-life
- ~36-48 h
- Route tags
- Route-dependent / verify
- Evidence level
- Approved/Preclinical
- Clinical status
- Approved cardiac drug; senolytic use not approved
- Value-for-money score
- 1 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Very low value for longevity due narrow therapeutic index and toxicity risk